2020 ASCO Annual Meeting - Conference Program - Clin Onc 2020 - 22991 | CCO
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Shannon Westin on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve complete resection -
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
Shannon Westin on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" / X
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
IJGC on X: "#podcast: The DESKTOP III Trial with Philipp Harter This week, @pedroramirezMD is joined by Prof. Philipp Harter to discuss The DESKTOP III Trial. ♫https://t.co/CZQXdMT97W @_kem @IGCSociety @ESGO_society @OncoAlert @agz_eriksson #
Minicorso di metodologia della ricerca clinica: I trial sui NAO insegnano – Prato,10 Ottobre 2023 – Executive Congress
Ovarian Committee. Closed Trials Upfront Surgery vs Neoadjuvant Chemotherapy Patients closed / 550 Leading EORTC Participating NCIC CTG Presentation. - ppt download
Shannon Westin on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve complete resection -
Diapositiva 1
New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
Shannon Westin on X: "Cross trial comparisons are always tricky...but, comparing the survival curves between the trials gives great pause - the GOG213 medians are markedly higher. Many thanks to @rcoledude for
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Surgery Can Improve Survival in Recurrent Ovarian Cancer
Research Update on Ovarian Cancer | PPT
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer - ecancer
First-in-human phase I trial to assess the ef | EurekAlert!
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma | MedPage Today
ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate
